Claims for Patent: 9,895,345

Summary for Patent: 9,895,345

Title:	Use of Lappaol F to inhibit tumor cell growth
Abstract:	Provided is a method for inhibiting the growth of tumor cells comprising administering to an individual in need of treatment, a composition comprising a therapeutically effective amount of Lappaol F. Also provided are compositions comprising Lappaol F and a pharmaceutically acceptable carrier.
Inventor(s):	Huang; Ying (Manlius, NY), Hu; Yingjie (Guangzhou, CN), Sun; Qing (Acton, MA), Liu; Kanglun (Guangzhou, CN), Shen; Xiaoling (Guangzhou, CN), Sheikh; M. Saeed (Manlius, NY)
Assignee:	The Research Foundation for the State University of New York (Syracuse, NY) Guangzhou University of Chinese Medicine (Guangzhou, CN)
Application Number:	14/889,534
Patent Claims:	1. A method of treatment of cancer comprising administering to an individual in need of treatment an effective amount of isolated and purified Lappaol F in a pharmaceutically acceptable carrier, wherein the Lappaol F is at least 99% pure as determined by HPLC, wherein administration of isolated Lappaol F results in inhibition of tumor growth, and wherein the individual in need of treatment is an individual afflicted with breast cancer, lung cancer, colon cancer, leukemia, melanoma, osteosarcoma, or cervical cancer. 2. The method of claim 1, wherein the Lappaol F is administered by a route that avoids first-pass metabolism. 3. The method of claim 2, wherein the route comprises intravenous, parenteral, intratumoral, intrapulmomnary, intranasal, intracranial or subcutaneous administration. 4. The method of claim 3, wherein the administration is performed prior to, concurrently with, or subsequent to chemotherapy, surgical treatment, or radiation treatment of the individual. 5. The method of claim 1, wherein the individual has not responded to treatment with a chemotherapeutic agent. 6. The method of claim 1, wherein the cancer cells exhibit a mutant-p53 or a wild type p53. 7. The method of claim 1, wherein the cancer cells are present in a tumor. 8. The method of claim 5, wherein the cancer cells exhibit a mutant p53. 9. The method of claim 5, wherein the cancer cells exhibit a wild type p53. 10. The method of claim 1, wherein the Lappaol F is administered with at least one additional chemotherapeutic agent. 11. The method of claim 10, wherein the at least one additional chemotherapeutic agent is selected from the group consisting of Cisplatin, Doxorubicin, Etoposide, Bleomycin, Cetuximab, Trastuzumab, a vinca alkaloid, a taxane, colchicine, and combinations thereof. 12. The method of claim 1, wherein the individual in need of treatment has been diagnosed with a tumor. 13. The method of claim 1, wherein Lappaol F is administered at a dose of from 1 mg/kg/day to 10 mg/kg/day. 14. The method of claim 13, wherein Lappaol F is administered for from 1 day to 30 days.

Details for Patent 9,895,345

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2033-05-07
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2033-05-07
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2033-05-07
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2033-05-07
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2033-05-07